- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 17.03. | ImageneBio, Inc.: ImageneBio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 1 | GlobeNewswire (USA) | ||
| 10.03. | ImageneBio, Inc. GAAP EPS of -$9.64 | 1 | Seeking Alpha | ||
| 10.03. | ImageneBio, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 2 | SEC Filings | ||
| 10.03. | ImageneBio, Inc. - 10-K, Annual Report | - | SEC Filings | ||
| 10.03. | ImageneBio, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 10.02. | ImageneBio appoints Dr. Porter-Brown as Chief Medical Officer | 1 | Investing.com | ||
| 10.02. | ImageneBio, Inc.: ImageneBio Appoints Immunology Drug Development Veteran Dr. Ben Porter-Brown as Chief Medical Officer | 979 | GlobeNewswire (Europe) | Brings 20+ years of clinical development experience in autoimmune and inflammatory diseases, including OX40/OX40L program leadership Will build and lead Imagene's clinical organization and drive completion... ► Artikel lesen | |
| 18.12.25 | ImageneBio, Inc. - 8-K, Current Report | - | SEC Filings | ||
| IMAGENEBIO Aktie jetzt für 0€ handeln | |||||
| 25.11.25 | ImageneBio: Wedbush startet Coverage mit negativem Votum und Kursziel 2 US-Dollar | 2 | Investing.com Deutsch | ||
| 25.11.25 | Wedbush assumes coverage of ImageneBio stock with Underperform rating | 2 | Investing.com | ||
| 19.11.25 | ImageneBio, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 12.11.25 | ImageneBio, Inc. GAAP EPS of -$2.91 | 1 | Seeking Alpha | ||
| 12.11.25 | ImageneBio, Inc. - S-8, Securities to be offered to employees in employee benefit plans | - | SEC Filings | ||
| 12.11.25 | ImageneBio, Inc.: ImageneBio Reports Third Quarter 2025 Financial Results and Provides IMG-007 Program Update Following Closing of Reverse Merger, Concurrent Financing, and Strengthening of Management Team | 478 | GlobeNewswire (Europe) | $142.6 million cash and cash equivalents and marketable securities as of September 30, 2025 Protocol amendment for ongoing Phase 2b ADAPTIVE study of IMG-007 in atopic dermatitis (AD) announced to... ► Artikel lesen | |
| 12.11.25 | ImageneBio, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 05.11.25 | ImageneBio, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 22.10.25 | ImageneBio ernennt CEO Kristin Yarema zur Interims-Finanzchefin | 2 | Investing.com Deutsch | ||
| 22.10.25 | ImageneBio, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 10.10.25 | ImageneBio, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 01.08.25 | ImageneBio, Inc.: ImageneBio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 215 | GlobeNewswire (Europe) | SAN DIEGO, Aug. 01, 2025 (GLOBE NEWSWIRE) -- ImageneBio, Inc. (Nasdaq: IMA) ("ImageneBio"), a clinical stage biotechnology company dedicated to developing treatments for immunological/autoimmune and... ► Artikel lesen |
1 2 Weiter >>
24 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EVOTEC | 4,270 | -0,81 % | Evotec streicht 800 Stellen - und trotzdem sehen Analysten 100% Kurspotenzial | 800 Stellen weg, Kosten explodiert, Gewinne verschoben - Evotec steckt tief in der Krise. Doch Analysten sehen mehr als 100% Kurspotenzial. Was steckt hinter dem Widerspruch? Rund 800 Stellen werden... ► Artikel lesen | |
| BIOGEN | 163,75 | +0,09 % | Biogen Sayd FDA Grants Approval For High-Dose SPINRAZA Regimen For SMATreatment | WESTON (dpa-AFX) - Biogen Inc. (BIIB) announced Monday that the High Dose Regimen of SPINRAZA (nusinersen), which is comprised of 50 mg/5 mL and 28 mg/5 mL doses, was approved by the U.S. Food... ► Artikel lesen | |
| VIKING THERAPEUTICS | 26,190 | +0,27 % | Viking Therapeutics, Inc.: Viking Therapeutics Announces Completion of Enrollment in Phase 3 VANQUISH-2 Trial of VK2735 | 78-Week Study Evaluating Subcutaneous VK2735 in Adults with Obesity and Type 2 Diabetes
SAN DIEGO, March 26, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking)... ► Artikel lesen | |
| MAINZ BIOMED | 0,416 | -1,54 % | MAINZ BIOMED N.V. - 8-K, Current Report | ||
| TREVENA | 4,000 | +1.983 % | TREVENA INC - 8-K, Current Report | ||
| ABIVAX | 89,10 | 0,00 % | Abivax-Aktie: Übernahmephantasie verflogen? | Das französische Biotechunternehmen Abivax hat mit der Veröffentlichung seiner Geschäftszahlen für 2025 und einem aktuellen Unternehmensupdate die Aufmerksamkeit der Märkte wieder stärker auf operative... ► Artikel lesen | |
| GALAPAGOS NV | 25,420 | 0,00 % | Galapagos NV: Galapagos Publishes 2025 Annual Report and Announces Annual and Extraordinary Shareholders' Meetings | Mechelen, Belgium; March 26, 2026, 21:01 CET; regulated information - Galapagos NV (Euronext & NASDAQ: GLPG) today published its annual report for the financial year 2025 and announced that its Annual... ► Artikel lesen | |
| CELLECTAR BIOSCIENCES | 2,750 | -2,14 % | Cellectar Biosciences, Inc.: Cellectar Biosciences Reports Financial Results for Year Ended 2025 and Provides Corporate Updates | On track to submit Conditional Marketing Authorization for iopofosine I 131 to European Medicines Agency in Q3 2026 for potential 2027 EU commercialization as a treatment for Waldenström Macroglobulinemia... ► Artikel lesen | |
| CARDIFF ONCOLOGY | 1,368 | +0,74 % | Craig-Hallum bestätigt 'Buy'-Rating für Cardiff Oncology mit Kursziel von 10 US-Dollar | ||
| CYTOKINETICS | 54,50 | -0,91 % | Cytokinetics, Incorporated: Cytokinetics Reports Fourth Quarter 2025 Financial Results and Provides Business Update | MYQORZO® Approved for Adults with Symptomatic Obstructive HCM in U.S., China and Europe; U.S. Launch Underway with First Prescriptions Dispensed within Days of Drug Availability Supplemental NDA for... ► Artikel lesen | |
| CYTOMX THERAPEUTICS | 3,824 | -0,31 % | CytomX Therapeutics (CTMX) Gains Analyst Confidence on Trial Progress | ||
| COHERUS ONCOLOGY | 1,381 | -0,83 % | Coherus Oncology, Inc.: Coherus Oncology Reports Full Year and Fourth Quarter 2025 Financial Results and Provides Business Update | - LOQTORZI net revenue more than doubled to $40.8 million in 2025 from $19.1 million in 2024 - - Reduced secured and convertible debt by 90% from $480 million to $38.8 million over 2024-2025 - - $172.1... ► Artikel lesen | |
| SENSEI BIOTHERAPEUTICS | 24,960 | -9,89 % | Sensei BioTherapeutics GAAP EPS of -$16.72 | ||
| SPERO THERAPEUTICS | 1,988 | +1,43 % | Spero Therapeutics, Inc.: Spero Therapeutics Announces Fourth Quarter and Full Year 2025 Operating Results and Provides a Business Update | Spero announced the resubmission of tebipenem HBr New Drug Application (NDA) to the FDA for complicated urinary tract infections (cUTI), including pyelonephritis in December 2025In February, Spero's... ► Artikel lesen | |
| REGENXBIO | 6,900 | +1,47 % | REGENXBIO Inc.: Regenxbio Reports New Positive Interim Data From Phase I/ii Affinity Duchenne Trial Of Rgx-202 | Investigational RGX-202 continues to demonstrate evidence of positively changing disease trajectory for Duchenne
Pivotal dose participants exceeded external controls across... ► Artikel lesen |
Das Unternehmen IMAGENEBIO INC kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 5,000 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu IMAGENEBIO INC finden Sie auf Wallstreet Online.